SGN-30
drugOn this page
Summary
Sgn-30 (CHEMBL2109256) is a phase-3 clinical-stage unknown; indicated across 6 conditions including lymphoma and lymphoid neoplasm.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Unknown
- Indications: 6 conditions
- Clinical trials: 3
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2109256 |
| Name | SGN-30 |
| Type | Unknown |
| Max phase | 3 |
Also known as: Sgn-30, SGN-30
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
6 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| lymphoma | 2 | MONDO:0005062 | EFO:0000574 |
| lymphoid neoplasm | 2 | MONDO:0005157 | EFO:0001642 |
| anaplastic large cell lymphoma | 2 | MONDO:0020325 | EFO:0003032 |
| Hodgkins lymphoma | 1 | MONDO:0004952 | EFO:0000183 |
| Kaposi’s sarcoma | 1 | MONDO:0005055 | EFO:0000558 |
| primary cutaneous T-cell non-Hodgkin lymphoma | 1 | MONDO:0000607 | EFO:0002913 |
Clinical trials
Total trials: 3.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 3 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00079755 | PHASE2 | COMPLETED | Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent Anaplastic Large Cell Lymphoma |
| NCT00099255 | PHASE2 | COMPLETED | Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma |
| NCT00365274 | PHASE2 | TERMINATED | SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.